MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $29.86 | Prev. Close $30.00 | Circuit Range N/A |
Day Range $29.21 - $31.15 | Year Range $9.43 - $45.61 | Volume 52,154 |
Average Traded $30.29 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
10-Jun-26 | $29.86 | $31.01 | +0.00% |
10-Jun-26 | $29.86 | $31.01 | +3.66% |
09-Jun-26 | $29.36 | $29.91 | +3.16% |
08-Jun-26 | $30.78 | $29.00 | -4.16% |
05-Jun-26 | $30.68 | $30.26 | -2.29% |
04-Jun-26 | $30.69 | $30.97 | +2.79% |
03-Jun-26 | $30.26 | $30.13 | -1.89% |